Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Adintrevimab

Copy Product Info
😃Good
Catalog No. T76900Cas No. 2516243-54-0
Alias ADG 20

Adintrevimab (ADG20) is a broad-spectrum neutralizing monoclonal antibody targeting SARS-CoV-2. It binds to a highly conserved epitope within the receptor-binding domain (RBD) of the spike glycoprotein, blocking its interaction with the ACE2 receptor. The Fc region is modified to extend its in vivo half-life. Research demonstrates potent neutralizing activity against various variants including Alpha, Beta, Gamma, and Delta, although its activity is significantly reduced against certain Omicron sub-lineages.

Adintrevimab

Adintrevimab

Copy Product Info
😃Good
Catalog No. T76900Alias ADG 20Cas No. 2516243-54-0
Adintrevimab (ADG20) is a broad-spectrum neutralizing monoclonal antibody targeting SARS-CoV-2. It binds to a highly conserved epitope within the receptor-binding domain (RBD) of the spike glycoprotein, blocking its interaction with the ACE2 receptor. The Fc region is modified to extend its in vivo half-life. Research demonstrates potent neutralizing activity against various variants including Alpha, Beta, Gamma, and Delta, although its activity is significantly reduced against certain Omicron sub-lineages.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$2472-4 weeks2-4 weeks
5 mg$6472-4 weeks2-4 weeks
10 mg$9872-4 weeks2-4 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Adintrevimab (ADG20) is a broad-spectrum neutralizing monoclonal antibody targeting SARS-CoV-2. It binds to a highly conserved epitope within the receptor-binding domain (RBD) of the spike glycoprotein, blocking its interaction with the ACE2 receptor. The Fc region is modified to extend its in vivo half-life. Research demonstrates potent neutralizing activity against various variants including Alpha, Beta, Gamma, and Delta, although its activity is significantly reduced against certain Omicron sub-lineages.
In vitro
In vitro, Adintrevimab demonstrates potent neutralization against SARS-CoV-2 variants (Alpha to Delta) by binding a conserved RBD epitope, though it shows diminished activity against Omicron BA.1 and lacks activity against BA.2-BA.5 sub-lineages [1].
In vivo
In prophylactic studies using Syrian golden hamsters (5-6-week-old females) infected with SARS-CoV-2/WA1/2020, single intraperitoneal administration of Adintrevimab (9.25 to 2,000 μg, approx. 0.1 to 20 mg/kg) provided dose-dependent protection, significantly reducing lung viral load and alleviating virus-induced lung pathology [1].
SynonymsADG 20
Reactivity
Virus
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetSARS-CoV-2
Chemical Properties
Cas No.2516243-54-0
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Adintrevimab | purchase Adintrevimab | Adintrevimab cost | order Adintrevimab | Adintrevimab in vivo | Adintrevimab in vitro